<?xml version='1.0' encoding='utf-8'?>
<document id="26808255"><sentence text="Pharmacokinetics and Pulmonary Distribution of Clarithromycin and Rifampicin after Concomitant and Consecutive Administration in Foals."><entity charOffset="47-61" id="DDI-PubMed.26808255.s1.e0" text="Clarithromycin" /><entity charOffset="66-76" id="DDI-PubMed.26808255.s1.e1" text="Rifampicin" /><pair ddi="false" e1="DDI-PubMed.26808255.s1.e0" e2="DDI-PubMed.26808255.s1.e0" /><pair ddi="false" e1="DDI-PubMed.26808255.s1.e0" e2="DDI-PubMed.26808255.s1.e1" /></sentence><sentence text="Drug interactions often result from multiple pharmacokinetic changes, such as after rifampicin (RIF) and clarithromycin (CLA) in the treatment of abscessing lung diseases"><entity charOffset="84-94" id="DDI-PubMed.26808255.s2.e0" text="rifampicin" /><entity charOffset="96-99" id="DDI-PubMed.26808255.s2.e1" text="RIF" /><entity charOffset="105-119" id="DDI-PubMed.26808255.s2.e2" text="clarithromycin" /><entity charOffset="121-124" id="DDI-PubMed.26808255.s2.e3" text="CLA" /><pair ddi="false" e1="DDI-PubMed.26808255.s2.e0" e2="DDI-PubMed.26808255.s2.e0" /><pair ddi="false" e1="DDI-PubMed.26808255.s2.e0" e2="DDI-PubMed.26808255.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26808255.s2.e0" e2="DDI-PubMed.26808255.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26808255.s2.e0" e2="DDI-PubMed.26808255.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26808255.s2.e1" e2="DDI-PubMed.26808255.s2.e1" /><pair ddi="false" e1="DDI-PubMed.26808255.s2.e1" e2="DDI-PubMed.26808255.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26808255.s2.e1" e2="DDI-PubMed.26808255.s2.e3" /><pair ddi="false" e1="DDI-PubMed.26808255.s2.e2" e2="DDI-PubMed.26808255.s2.e2" /><pair ddi="false" e1="DDI-PubMed.26808255.s2.e2" e2="DDI-PubMed.26808255.s2.e3" /></sentence><sentence text=" Comedication of RIF may interact with CLA disposition by either induction of presystemic elimination processes and/or inhibition of uptake mechanisms because it regulates gene transcription and modulates function of various CYP enzymes, multidrug efflux and uptake transporters for which CLA is a substrate"><entity charOffset="17-19" id="DDI-PubMed.26808255.s3.e0" text="RIF" /><entity charOffset="39-41" id="DDI-PubMed.26808255.s3.e1" text="CLA" /><entity charOffset="289-291" id="DDI-PubMed.26808255.s3.e2" text="CLA" /><pair ddi="false" e1="DDI-PubMed.26808255.s3.e0" e2="DDI-PubMed.26808255.s3.e0" /><pair ddi="false" e1="DDI-PubMed.26808255.s3.e0" e2="DDI-PubMed.26808255.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26808255.s3.e0" e2="DDI-PubMed.26808255.s3.e2" /><pair ddi="false" e1="DDI-PubMed.26808255.s3.e1" e2="DDI-PubMed.26808255.s3.e1" /><pair ddi="false" e1="DDI-PubMed.26808255.s3.e1" e2="DDI-PubMed.26808255.s3.e2" /></sentence><sentence text=" To distinguish the transcriptional changes from the modulating interaction components upon CLA absorption and pulmonary distribution, we initiated a repeated-dose study in 12 healthy foals with CLA (7"><entity charOffset="92-94" id="DDI-PubMed.26808255.s4.e0" text="CLA" /><entity charOffset="195-197" id="DDI-PubMed.26808255.s4.e1" text="CLA" /><pair ddi="false" e1="DDI-PubMed.26808255.s4.e0" e2="DDI-PubMed.26808255.s4.e0" /><pair ddi="false" e1="DDI-PubMed.26808255.s4.e0" e2="DDI-PubMed.26808255.s4.e1" /></sentence><sentence text="5 mg/kg, p" /><sentence text="o" /><sentence text=", b" /><sentence text="i" /><sentence text="d" /><sentence text=") in comedication with RIF (10 mg/kg, p"><entity charOffset="23-25" id="DDI-PubMed.26808255.s10.e0" text="RIF" /></sentence><sentence text="o" /><sentence text=", b" /><sentence text="i" /><sentence text="d" /><sentence text=") given either concomitantly with CLA or consecutively 4 h after CLA"><entity charOffset="34-36" id="DDI-PubMed.26808255.s15.e0" text="CLA" /><entity charOffset="65-67" id="DDI-PubMed.26808255.s15.e1" text="CLA" /><pair ddi="false" e1="DDI-PubMed.26808255.s15.e0" e2="DDI-PubMed.26808255.s15.e0" /><pair ddi="false" e1="DDI-PubMed.26808255.s15.e0" e2="DDI-PubMed.26808255.s15.e1" /></sentence><sentence text=" Affinity of CLA to human P-gp, MRP2, and MRP3 and to OCT1, OCT3, and PEPT1 was measured using Sf9-derived inside-out membrane vesicles and transfected HEK293 cells, respectively"><entity charOffset="13-15" id="DDI-PubMed.26808255.s16.e0" text="CLA" /></sentence><sentence text=" ABCB1 (P-gp) induction by RIF and affinity of CLA to equine P-gp were studied using primary equine hepatocytes"><entity charOffset="27-29" id="DDI-PubMed.26808255.s17.e0" text="RIF" /><entity charOffset="47-49" id="DDI-PubMed.26808255.s17.e1" text="CLA" /><pair ddi="false" e1="DDI-PubMed.26808255.s17.e0" e2="DDI-PubMed.26808255.s17.e0" /><pair ddi="false" e1="DDI-PubMed.26808255.s17.e0" e2="DDI-PubMed.26808255.s17.e1" /></sentence><sentence text=" Absolute bioavailability of CLA was reduced from ∼40% to below 5% after comedication of RIF in both schedules of administration, and Tmax occurred ∼2-3 h earlier"><entity charOffset="89-91" id="DDI-PubMed.26808255.s18.e0" text="RIF" /><entity charOffset="29-31" id="DDI-PubMed.26808255.s18.e1" text="CLA" /><pair ddi="false" e1="DDI-PubMed.26808255.s18.e1" e2="DDI-PubMed.26808255.s18.e1" /><pair ddi="false" e1="DDI-PubMed.26808255.s18.e1" e2="DDI-PubMed.26808255.s18.e0" /></sentence><sentence text=" The loss of bioavailability was not associated with increased 14-hydroxyclarithromycin (14-OH-CLA) exposure"><entity charOffset="63-87" id="DDI-PubMed.26808255.s19.e0" text="14-hydroxyclarithromycin" /><entity charOffset="89-98" id="DDI-PubMed.26808255.s19.e1" text="14-OH-CLA" /><entity charOffset="95-103" id="DDI-PubMed.26808255.s19.e2" text="CLA" /><pair ddi="false" e1="DDI-PubMed.26808255.s19.e0" e2="DDI-PubMed.26808255.s19.e0" /><pair ddi="false" e1="DDI-PubMed.26808255.s19.e0" e2="DDI-PubMed.26808255.s19.e1" /><pair ddi="false" e1="DDI-PubMed.26808255.s19.e0" e2="DDI-PubMed.26808255.s19.e2" /><pair ddi="false" e1="DDI-PubMed.26808255.s19.e1" e2="DDI-PubMed.26808255.s19.e1" /><pair ddi="false" e1="DDI-PubMed.26808255.s19.e1" e2="DDI-PubMed.26808255.s19.e2" /></sentence><sentence text=" After consecutive dosing, absolute bioavailability and pulmonary penetration of CLA increased ∼2-fold compared to concomitant use"><entity charOffset="81-83" id="DDI-PubMed.26808255.s20.e0" text="CLA" /></sentence><sentence text=" In vitro, CLA showed affinity to human and equine P-gp"><entity charOffset="11-13" id="DDI-PubMed.26808255.s21.e0" text="CLA" /></sentence><sentence text=" Expression of ABCB1 mRNA was upregulated by RIF in 7 of 8 duodenal biopsy specimens and in primary equine hepatocytes"><entity charOffset="45-47" id="DDI-PubMed.26808255.s22.e0" text="RIF" /></sentence><sentence text=" In conclusion, the major undesired influence of RIF on oral absorption and pulmonary distribution of CLA is associated with induction of intestinal P-gp"><entity charOffset="49-51" id="DDI-PubMed.26808255.s23.e0" text="RIF" /><entity charOffset="102-104" id="DDI-PubMed.26808255.s23.e1" text="CLA" /><pair ddi="false" e1="DDI-PubMed.26808255.s23.e0" e2="DDI-PubMed.26808255.s23.e0" /><pair ddi="false" e1="DDI-PubMed.26808255.s23.e0" e2="DDI-PubMed.26808255.s23.e1" /></sentence><sentence text=" Consecutive administration to avoid competition with its intestinal uptake transport results in significantly, although not clinically relevant, improved systemic exposure" /><sentence text="" /></document>